Fate Therapeutics (FATE) PT Lowered to $2.20 at BofA Securities
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $2.20 (from $2.50) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
